OasisLMS

Upon completion of this activity, participants should be able to:

• Advance mechanistic insight into liver–organ crosstalk (gut/microbiome, immune system, brain, adipose tissue) and its disruption in MASLD, MASH, ALD, cholestatic disease, and other liver disorders.
• Explore novel technologies and interventions, including microbiome-targeted therapies, gut–liver axis modulation, and cell- and nanoparticle-based strategies, to restore homeostasis and treat liver disease.
• Promote interdisciplinary collaboration among basic, translational, and clinical scientists to accelerate discovery and therapeutic innovation.
• Support the development of early-career investigators through mentorship, visibility, and opportunities to present and engage in discussion.

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this enduring material activity for a maximum of 8.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date:  May 28, 2026
Expiration Date: May 28, 2027

This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Marie-Clare Arrieta:
Speakers Bureau: Biocodex

Jasmohan Bajaj, MD, FAASLD:
Consultant: Boehringer-Ingelheim
Research Grant: Grifols, Bausch, Sequana

Bernd Schnabl, MD, FAASLD:
Consultant: Boehringer Ingelheim, Mabwell Therapeutics, Surrozen
Corporate Board Member: Nterica
Research Grant: Axial Biotherapeutics,ChromoLogic, CymaBay Therapeutics, Intercept Pharmaceuticals, Prodigy Biotech

Mark Swain, MD, MSC, FAASLD, FCAAS:
Scientific Medical Advisory Board Member: Gilead, Ipsen, Novo Nordisk, Advanz, Abbott, GSK, Mirum, Boehringer Ingelheim.
Speakers Bureau: Ipsen, Gilead, Umecrine
Research Grant: Gilead, BMS, GSK, Cymabay, Intercept, Kowa, Novo Nordisk, Pfizer, Ancella, Merck, Galectin, Calliditas, Ipsen, Madrigal, Roche, Altimmune, 89Bio, Inventiva, Boehringer Ingelheim

All others involved in content development including planners, speakers and staff have nothing to disclose.

https://www.aasld.org/terms-use-and-privacy-policy